Developer docs
API playgroundTry for free, no card

Search company profiles

Curie.Bio

Full company profile

uuid00009gb

Namestring
Curie.Bio
Legal namestring
Curie.Bio
Websiteurl
curie.bio
Company typeenum
Private
Founded yearint
2022
Short descriptiontext

Curie.Bio is a Boston-based biotech venture capital firm founded in 2022 that provides capital and operating support to founders developing novel clinical-stage therapeutics. The firm is backed by tier-1 investors including ARCH, Andreessen Horowitz, and Google Ventures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biotech venture capital, therapeutics funding, life science investing, biotech startup support, clinical-stage financing
Industry3 codes
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Open-End Investment Funds525910
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Biotech Venture Capital
Social media profiles1 record
Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Curie.Bio is a venture capital firm that provides funding and support to founders building clinical-stage biotech companies developing novel therapeutics. The firm operates a hands-on VC model that helps founders discover and develop important new medicines, participating in financing rounds alongside other institutional investors.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Curie.Bio is a life science venture capital firm. Based on the source data reviewed, no specific products, services, or technology platforms are described. The website contains standard navigation pages (Home, Our Team, Founder Guide, Life at Curie.Bio, Connect, Careers, Privacy Policy, Terms & Conditions) but no detailed product or service offerings are presented in the scraped content.

Product and service1 record
1Biotech Founder Funding & Support
CategoryVenture Capital / Biotech Investment
Description

Venture capital investment and strategic support program for biotech founders building clinical-stage therapeutic companies, providing capital to advance drug development programs.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston-based early-stage biotech venture firm that builds and funds new therapeutic companies from inception — closely analogous to Curie.Bio's co-builder model for founders developing new medicines.

TypeDirect peer
Description

Biotech innovation platform that originates and develops new therapeutic companies, operating an 'invention-first' model with embedded R&D support — directly comparable to Curie.Bio's founder-support thesis.

TypeDirect peer
Description

Boston-based biotech VC that creates and launches new therapeutic companies with operational involvement from formation — a near-analogous model to Curie.Bio's hands-on approach.

TypeDirect peer
Description

Healthcare and biotech-focused investment firm investing across public and private stages of drug development — directly comparable in therapeutic-area focus and stage.

TypeDirect peer
Description

Healthcare-dedicated investment firm funding therapeutics, medical devices, and diagnostics across stages — analogous as a specialist biotech investment platform.

TypeDirect peer
Description

Premier biotech-focused VC firm investing in early-stage life sciences companies; also a known backer of Curie.Bio, making it both a peer and a relationship-relevant investor.

TypeDirect peer
Description

Biotech-focused venture fund investing in early- and growth-stage therapeutics and techbio companies — comparable as a specialist biotech investor.

TypeDirect peer
Description

a16z's bio/health fund invests across stages of biotech and digital health with operational support — a peer with similar scale ambitions, also an existing LP/backer of Curie.Bio.

TypeBroad incumbent
Description

Large diversified VC firm with a substantial healthcare and biotech practice — comparable as a generalist with deep biotech capabilities, though broader in scope than Curie.Bio's specialist focus.

TypeDirect peer
Description

Healthcare-focused investment firm that provides capital and operational expertise across the life sciences — analogous as a specialist investor supporting therapeutic development companies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment13 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curie.Bio

Biotech Venture Capitalcurie.bio

Curie.Bio is a Boston-based biotech venture capital firm founded in 2022 that provides capital and operating support to founders developing novel clinical-stage therapeutics. The firm is backed by tier-1 investors including ARCH, Andreessen Horowitz, and Google Ventures.

Curie.Bio firmographics

Firmographics
Name
Curie.Bio
Legal name
Curie.Bio
Website
https://curie.bio
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
101–250 employees
Short description
Curie.Bio is a Boston-based biotech venture capital firm founded in 2022 that provides capital and operating support to founders developing novel clinical-stage therapeutics. The firm is backed by tier-1 investors including ARCH, Andreessen Horowitz, and Google Ventures.
Ownership category
akta.pro rank

Curie.Bio industry classification

Industry
Product category
Biotech Venture Capital
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Open-End Investment Funds (525910)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Biotech venture capital
  • Therapeutics funding
  • Life science investing
  • Biotech startup support
  • Clinical-stage financing

Where Curie.Bio is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Curie.Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Curie.Bio product offering

Product offering

Core offering

Curie.Bio is a venture capital firm that provides funding and support to founders building clinical-stage biotech companies developing novel therapeutics. The firm operates a hands-on VC model that helps founders discover and develop important new medicines, participating in financing rounds alongside other institutional investors.

Product overview

Curie.Bio is a life science venture capital firm. Based on the source data reviewed, no specific products, services, or technology platforms are described. The website contains standard navigation pages (Home, Our Team, Founder Guide, Life at Curie.Bio, Connect, Careers, Privacy Policy, Terms & Conditions) but no detailed product or service offerings are presented in the scraped content.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biotech Founder Funding & Support Venture capital investment and strategic support program for biotech founders building clinical-stage therapeutic companies, providing capital to advance drug development programs.

Companies that use Curie.Bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Curie.Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Curie.Bio partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights4 records

Curie.Bio competitors and assessment

Company assessment

Direct peers

  • Atlas Venture: Boston-based early-stage biotech venture firm that builds and funds new therapeutic companies from inception — closely analogous to Curie.Bio's co-builder model for founders developing new medicines.
  • Flagship Pioneering: Biotech innovation platform that originates and develops new therapeutic companies, operating an 'invention-first' model with embedded R&D support — directly comparable to Curie.Bio's founder-support thesis.
  • Third Rock Ventures: Boston-based biotech VC that creates and launches new therapeutic companies with operational involvement from formation — a near-analogous model to Curie.Bio's hands-on approach.
  • RA Capital Management: Healthcare and biotech-focused investment firm investing across public and private stages of drug development — directly comparable in therapeutic-area focus and stage.
  • OrbiMed: Healthcare-dedicated investment firm funding therapeutics, medical devices, and diagnostics across stages — analogous as a specialist biotech investment platform.
  • ARCH Venture Partners: Premier biotech-focused VC firm investing in early-stage life sciences companies; also a known backer of Curie.Bio, making it both a peer and a relationship-relevant investor.
  • Section 32: Biotech-focused venture fund investing in early- and growth-stage therapeutics and techbio companies — comparable as a specialist biotech investor.
  • Andreessen Horowitz (Bio Fund): a16z's bio/health fund invests across stages of biotech and digital health with operational support — a peer with similar scale ambitions, also an existing LP/backer of Curie.Bio.
  • Deerfield Management: Healthcare-focused investment firm that provides capital and operational expertise across the life sciences — analogous as a specialist investor supporting therapeutic development companies.

Broad incumbents

  • New Enterprise Associates (NEA): Large diversified VC firm with a substantial healthcare and biotech practice — comparable as a generalist with deep biotech capabilities, though broader in scope than Curie.Bio's specialist focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Curie.Bio social profiles

Digital presence

Curie.Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curie.Bio leadership team

Management profile

Number of profiles

Profiles7 records

Curie.Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curie.Bio M&A and investment

M&A and investment

M&A

Investments13 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curie.Bio

What does Curie.Bio do?

Curie.Bio is a venture capital firm that provides funding and support to founders building clinical-stage biotech companies developing novel therapeutics. The firm operates a hands-on VC model that helps founders discover and develop important new medicines, participating in financing rounds alongside other institutional investors.

Is Curie.Bio a public or private company?

Curie.Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Curie.Bio founded?

Curie.Bio was founded in 2022. It employs 101 to 250 people.

Where is Curie.Bio based?

Curie.Bio is headquartered in Boston, United States, in the North America region.

Who are Curie.Bio's main competitors?

Direct peers on record are Atlas Venture, Flagship Pioneering, Third Rock Ventures, RA Capital Management, OrbiMed, ARCH Venture Partners, Section 32, Andreessen Horowitz (Bio Fund) and Deerfield Management. New Enterprise Associates (NEA) is listed as a broad incumbent.

Does Curie.Bio have an API?

No public API is recorded for Curie.Bio.

What industry is Curie.Bio in?

Curie.Bio's product category is Biotech Venture Capital. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 525 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The New York TimesFearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share NothingU.S. biotech firms are adopting secrecy to prevent Chinese rivals from exploiting their discoveries. Alnylam, Strand Therapeutics, and Curie.Bio have policies to withhold unpublished data, avoid presentations, and delay patent filings. The shift reflects concerns that well-funded Chinese companies will quickly develop or duplicate new drugs.Clinical Trials ArenaR1 Therapeutics secures $80.5m to fund Phase IIb AP306 studyR1 Therapeutics expanded its Series A financing to $80.5m to advance AP306 in a Phase IIb trial for hyperphosphatemia in dialysis-dependent chronic kidney disease patients. The round includes Samsara BioCapital and expects top-line results in the first half of 2027.Venture Capital Access OnlineR1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemiaR1 Therapeutics expanded its Series A financing to $80.5 million, adding Samsara BioCapital to an existing syndicate. The funds will advance AP306, a pan phosphate transporter inhibitor in a global Phase 2b trial for hyperphosphatemia in dialysis patients, with topline data expected in H1 2027.BioSpaceR1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemiaR1 Therapeutics expanded its Series A financing to $80.5 million, adding Samsara BioCapital to an existing syndicate. The funds will advance AP306, a pan phosphate transporter inhibitor in a global Phase 2b trial for hyperphosphatemia in dialysis patients, with topline data expected in H1 2027.BioSpaceSOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS PatientsSOLA Biosciences Japan received a 6 billion yen grant from AMED to advance SOL-257, a gene therapy targeting misfolded TDP-43 in ALS. The therapy uses the JUMP70 platform to restore TDP-43 function, with development planned in Japan and the U.S. The company aims to reach human proof of concept.AacrInaugural AACR D3 Opens With Insights From Leaders Across Drug Discovery and DevelopmentThe inaugural AACR Drug Discovery and Development (D3) meeting was held July 21-24 in Boston, bringing together experts from academia, pharma, biopharma, biotech, regulatory agencies, and venture capital to discuss accelerating oncology drug development. Panelists from Pfizer, Curie.Bio, and Google Ventures discussed current challenges facing the biotech sector, including more selective investment funding, rising interest rates affecting companies, and concerns about stifled innovation from funding "me-better" versions of existing therapeutics. The speakers emphasized the importance of collaboration with Chinese researchers, incorporating AI into drug discovery, and forming consortiums for precompetitive validation of candidate targets to accelerate progress in cancer treatment.Longevity.TechnologyR1 launches with $77.5m for chronic kidney disease drugR1 Therapeutics has launched as a clinical-stage biotech with a $77.5 million Series A financing co-led by Abingworth, F-Prime and DaVita Venture Group, with participation from Curie.Bio, SymBiosis and US Renal Care, to advance AP306 for hyperphosphatemia in chronic kidney disease patients on dialysis. The company also secured an exclusive global licensing agreement with Alebund Pharmaceuticals outside Greater China for the drug candidate, which has demonstrated significant reduction in serum phosphate levels in a Phase 2a study, with a Phase 2b trial expected to begin later this year. The participation of dialysis providers DaVita and US Renal Care signals strategic investment from stakeholders directly familiar with the treatment gaps and high pill burden facing dialysis patients.R1TherapeuticsRenal-Focused BiotechR1 Therapeutics, a clinical-stage biopharmaceutical company focused on kidney disease, launched with a $77.5 million oversubscribed Series A financing co-led by Abingworth, F-Prime, and DaVita Venture Group, with participation from Curie.Bio, SymBiosis, and U.S. Renal Care. The company also secured exclusive global rights outside of Greater China from Alebund Pharmaceuticals for AP306, a first-in-class pan phosphate transporter inhibitor targeting hyperphosphatemia in chronic kidney disease patients on dialysis. Proceeds will fund a Phase 2b study planned to start later this year, with AP306 representing a differentiated approach as the only agent blocking active phosphate transport.The Pharma LetterSecarna Pharma and Curie.Bio expand partnershipSecarna Pharmaceuticals expanded its collaboration with Curie.Bio, announced in May 2025. The expansion includes Secarna's support in identifying oligonucleotide candidates using its proprietary OligoCreator platform for Curie.Bio's portfolio companies.STATBiotech and pharma executives on what Trump and RFK Jr. could mean for the industryBiotech and pharma executives are preparing for Trump's second term, with reactions ranging from optimism to skepticism. Bausch + Lomb CEO Brent Saunders said he is optimistic, while Curie.Bio CEO Zach Weinberg called RFK Jr. "scary and unqualified." Many leaders took a wait-and-see approach.